Unknown

Dataset Information

0

Clinical and Genome-Wide Analysis of Serum Platinum Levels after Cisplatin-Based Chemotherapy.


ABSTRACT: PURPOSE:Serum platinum is measurable for years after completion of cisplatin-based chemotherapy (CBC). We report the largest investigation of serum platinum levels to date of 1,010 testicular cancer survivors (TCS) assessed 1-35 years after CBC and evaluate genetic contributions to these levels. EXPERIMENTAL DESIGN:Eligible TCS given 300 or 400 (±15) mg/m2 cisplatin underwent extensive audiometric testing, clinical examination, completed questionnaires, and had crude serum platinum levels measured. Associations between serum platinum and various risk factors and toxicities were assessed after fitting a biexponential model adjusted for follow-up time and cumulative cisplatin dose. A genome-wide association study (GWAS) was performed using the serum platinum residuals of the dose and time-adjusted model. RESULTS:Serum platinum levels exceeded the reference range for approximately 31 years, with a strong inverse relationship with creatinine clearance at follow-up (age-adjusted P = 2.13 × 10-3). We observed a significant, positive association between residual platinum values and luteinizing hormone (age-adjusted P = 6.58 × 10-3). Patients with high residual platinum levels experienced greater Raynaud phenomenon than those with medium or low levels (age-adjusted ORhigh/low = 1.46; P = 0.04), as well as a higher likelihood of developing tinnitus (age-adjusted ORhigh/low = 1.68, P = 0.07). GWAS identified one single-nucleotide polymorphism (SNP) meeting genome-wide significance, rs1377817 (P = 4.6 × 10-8, a SNP intronic to MYH14). CONCLUSIONS:This study indicates that residual platinum values are correlated with several cisplatin-related toxicities. One genetic variant is associated with these levels.

SUBMITTER: Trendowski MR 

PROVIDER: S-EPMC6774840 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Purpose</h4>Serum platinum is measurable for years after completion of cisplatin-based chemotherapy (CBC). We report the largest investigation of serum platinum levels to date of 1,010 testicular cancer survivors (TCS) assessed 1-35 years after CBC and evaluate genetic contributions to these levels.<h4>Experimental design</h4>Eligible TCS given 300 or 400 (±15) mg/m<sup>2</sup> cisplatin underwent extensive audiometric testing, clinical examination, completed questionnaires, and had crude se  ...[more]

Similar Datasets

| S-EPMC8817086 | biostudies-literature
| S-EPMC2701336 | biostudies-literature
| S-EPMC10582065 | biostudies-literature
| S-EPMC7997802 | biostudies-literature
| S-EPMC5626588 | biostudies-other
| S-EPMC3096796 | biostudies-literature
| S-EPMC6903403 | biostudies-literature
| S-EPMC3723686 | biostudies-literature
| S-EPMC5264598 | biostudies-literature
| S-EPMC2928134 | biostudies-literature